Read this as the skin side of the same arc the rest of the site reads. Oestrogen withdrawal through the menopausal transition correlates with measurable reductions in skin collagen content and dermal thickness; the Maltese cohort series isolated this carefully across two decades of work.[01][02] What looks and feels like time on the skin in this window is, to a substantial extent, an oestrogen story rather than a chronology one. The interventions split cleanly: sun protection and topical actives sit on the photoageing side; oral nutrients sit alongside, not instead.
Three threads of the literature are mature enough to write about with confidence for a woman in this window: the oestrogen-and-collagen mechanism the Calleja-Agius and Brincat reviews map; the GB-authorised claim for vitamin C contribution to normal collagen formation for the normal function of skin, and the biotin and zinc claims that travel with it; and the randomised collagen-peptide trial base, summarised in the de Miranda 2021 meta-analysis of 19 RCTs.[04][10] Sunscreen sits above all three on the photoageing endpoint — the Hughes 2013 trial is the cleanest single piece of evidence on the page.[11]
What the research examines
Two ingredient categories on this page carry direct GB-authorised health claims for skin: vitamin C (normal collagen formation for the normal function of skin) and a set of B-vitamins and minerals via the “maintenance of normal skin” wording — biotin, niacin, riboflavin, vitamin A, zinc, iodine, with copper carrying the pigmentation-specific claim.[12] Oral collagen peptides and oral hyaluronic acid sit in the research-context tier — peer-reviewed trial work exists at instrument-measured endpoints, but no authorised health claim. Sunscreen and topical retinoids sit upstream of the supplement question entirely; the body of randomised evidence on photoageing prevention is topical, not oral.
